---
schema_version: "secwatch.filing_event.v1"
accession: "0001601485-24-000067"
form_type: "8-K"
ticker: "ELTX"
cik: "0001601485"
company_name: "Elicio Therapeutics, Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:34:47.589150+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Elicio reports ELI-002 Phase 1 data: T cell responses correlate with DFS; Phase 2 enrollment expected Q4 2024

## Summary
- All 12 evaluable patients showed mKRAS-specific T cell responses; RP2D group had 12-fold higher median response vs 1.4 mg group.
- T cell response magnitude correlated with DFS: lowest quartile mDFS 3.1 months (p=0.0027), top three quartiles not yet reached.
- Antigen spreading in 100% of RP2D-treated patients (n=6); T cells targeted 67.5% of patient-specific neoantigens.
- ELI-002 remains safe and well-tolerated; no dose-limiting toxicities or cytokine release syndrome observed.
- Phase 2 enrollment expected to complete in Q4 2024; interim event-driven DFS analysis expected H1 2025.

## SEC filing metadata
- accession: 0001601485-24-000067
- form_type: 8-K
- ticker: ELTX
- cik: 0001601485
- company_name: Elicio Therapeutics, Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000067/0001601485-24-000067-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601485/000160148524000067/angn-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601485-24-000067
- JSON: https://secwatch.observer/filing/0001601485-24-000067.json
- Plain text: https://secwatch.observer/filing/0001601485-24-000067.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.